|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 德鲁昔康>> 市场分析报告 |
德鲁昔康市场分析报告 |
|
Topoisomerase Inhibitors - Pipeline Insight, 2022 ... Drugs Datopotamab deruxtecan - Daiichi Sankyo Datopotamab deruxtecan is currently being ... and supply of datopotamab deruxtecan. It is currently in Phase III ... Products Datopotamab deruxtecan Aldoxorubicin Trastuzumab deruxtecan Camsirubicin LY 01610 ... Metastatic Colorectal cancer - Pipeline Insight, 2022 ... colorectal cancer. Trastuzumab Deruxtecan: Daiichi Sankyo Trastuzumab deruxtecan is a HER2 directed ... DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the ... expressed on cancer cells. Trastuzumab deruxtecan is comprised of a HER2 monoclonal antibody ... Global HER2 ADC Drugs Market Growth 2024-2030 ... ) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) represent a novel class of therapeutics ... emtansine? T-DXd?DS-8201?Enhertu?Trastuzumab deruxtecan? RC48?Disitamab vedotin? Segmentation by Application ... Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030 ... cancer patients eligible for trastuzumab deruxtecan (ENHERTU), which received a label expansion ... Biliary Tract Cancer - Pipeline Insight, 2021 ... TH-302 DKN-01 Surufatinib TQB2450 Trastuzumab deruxtecan Envafolimab SC-43 INCB001158 SO-C101 CT-0508 CX-4945 ... Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. 'Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026' Report Highlights: Global Cancer Antibody Drug ... Global Breast Cancer Drugs Market – By Drug Type (HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, CDK4/6 Inhibitors, and Hormonal Receptors), By Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up to 2025 ... with Daiichi Sankyo for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate ... Enhertu - Drug Insight and Market Forecast - 2030 ... global space. Drug Summary Trastuzumab deruxtecan, sold under the brand ... granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU, Daiichi Sankyo) ... Sankyo Company and AstraZeneca’s trastuzumab deruxtecan has been recommended for conditional ... US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. 'US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026' Report Highlights: US Cancer Antibodies Market Opportunity: > US$ 70 ... Biological Therapies for Cancer: Technologies and Global Markets REPORT SCOPE: This report provides an update on BIO048C Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments ... Global TROP2 Antibody Market & Clinical Trials Insight 2029 ... HR+/HER2- metastatic breast cancer. Datopotamab deruxtecan, another promising investigational TROP2-targeting ... DNA topoisomerase I inhibitors - Pipeline Insight, 2022 ... tumours. Trastuzumab Deruxtecan: Daiichi Sankyo Trastuzumab deruxtecan is a HER2 directed ... ADC scientific platform. Trastuzumab deruxtecan (5.4 mg/kg) is approved in the U.S. and ... Sacituzumab govitecan Trastuzumab deruxtecan Irinotecan sucrosofate DS-1062 ... US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights: US Cancer Antibodies Market Opportunity: > US$ ... Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028 Report Highlights: Global Breast Cancer Immunotherapy Market Opportunity ... Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031 ... trial series is currently assessing Datopotamab deruxtecan in a variety of solid tumors outside its ... Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts The global antibody drug conjugate market is expected to reach USD 7.72 billion by 2023 and is anticipated to grow at a CAGR of 9.63% during the forecast period 2023-2035 Antibody drug conjugates (ADCs) are a class of engineered therapeutics that combine ... Global Her2 Target Drugs Market Research Report 2025(Status and Outlook) ... -drug conjugates (e.g., trastuzumab emtansine, trastuzumab deruxtecan), and small-molecule tyrosine kinase ... Extensive-Stage Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major extensive-stage small cell lung cancer markets are expected to exhibit a CAGR of 7.6% during 2024-2034. The extensive-stage small cell lung cancer market has been comprehensively analyzed in IMARC's new report titled "Extensive-Stage Small Cell ... Gastroesophageal Junction Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major gastroesophageal junction adenocarcinoma markets are expected to exhibit a CAGR of 13.82% during 2024-2034. The gastroesophageal junction adenocarcinoma market has been comprehensively analyzed in IMARC's new report titled "Gastroesophageal ... Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major metastatic HER2-positive breast cancer markets are expected to exhibit a CAGR of 1.18% during 2024-2034. The metastatic HER2-positive breast cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic HER2-Positive ... |